설사형 과민성 장 증후군 남성 환자에게 사용되는 ramosetron 의 경제성 평가
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손현순 | - |
dc.contributor.author | 이태진 | - |
dc.contributor.author | 김선 | - |
dc.date.accessioned | 2021-10-01T01:40:15Z | - |
dc.date.available | 2021-10-01T01:40:15Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.issn | 1226-6051 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/52418 | - |
dc.description.abstract | This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that for ramosetron treatment with the price of KW910 for 5 μg tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine. But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In conclusion, ramosetron was a cost-effective regimen compared with trimebutine or trimebutine+loperamide from the societal perspective. | - |
dc.format.extent | 10 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 한국임상약학회 | - |
dc.title | 설사형 과민성 장 증후군 남성 환자에게 사용되는 ramosetron 의 경제성 평가 | - |
dc.title.alternative | Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | 한국임상약학회지, v.20, no.3, pp 268 - 277 | - |
dc.citation.title | 한국임상약학회지 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 268 | - |
dc.citation.endPage | 277 | - |
dc.identifier.kciid | ART001525314 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | cost-utility | - |
dc.subject.keywordAuthor | irritable bowel syndrome | - |
dc.subject.keywordAuthor | ramosetron | - |
dc.subject.keywordAuthor | trimebutine | - |
dc.subject.keywordAuthor | loperamide | - |
dc.identifier.url | https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001525314 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.